Phospho-ZFP36L1 (S92) Antibody

What is the functional significance of ZFP36L1 phosphorylation at S92?

Phosphorylation of ZFP36L1 at S92 by protein kinase B (PKB/Akt) serves as a critical regulatory mechanism that inhibits its mRNA-destabilizing activity. When PKB phosphorylates ZFP36L1 at S92, it:

• Does not impair ARE binding capability of ZFP36L1

• Induces complex formation with 14-3-3 scaffold proteins

• Sequesters ZFP36L1 from cellular decay-promoting machinery

• Leads to stabilization of ARE-containing mRNAs

This phosphorylation event represents a molecular switch that converts ZFP36L1 from an active mRNA-destabilizing factor to an inactive form, thereby allowing the expression of ARE-containing transcripts. In vivo and in vitro experiments support a model where PKB activation (such as through insulin signaling) causes ARE-mRNA stabilization by inactivating ZFP36L1 through this phosphorylation mechanism .

How does Phospho-ZFP36L1 (S92) antibody differ from other ZFP36L1 antibodies?

Phospho-ZFP36L1 (S92) antibodies specifically recognize ZFP36L1 when phosphorylated at serine 92, providing several distinct advantages:

The phospho-specific antibody can be effectively blocked by the phosphopeptide containing the S92 residue, but not by the corresponding non-phosphorylated peptide or peptides containing other phosphorylation sites, confirming its specificity .

In which cell types and tissues is phosphorylated ZFP36L1 (S92) commonly expressed?

Phosphorylated ZFP36L1 at S92 shows distinct expression patterns:

• Immune cells: Detected in T cells where ZFP36L1 acts as a sensor of TCR affinity and promotes the response to cytokines like IL-2

• Bronchial epithelial cells: Expression levels are altered in asthma patients, with decreased binding to polyribosomes observed in severe cases

• Cancer cells: Modified expression in various cancer types where ZFP36L1 functions as a tumor suppressor by regulating mRNA stability of hypoxia and cell-cycle-related transcripts

Importantly, phosphorylation at S92 increases in response to insulin stimulation through PKB/Akt activation and is partially inhibited by the PI3-K inhibitor wortmannin, indicating its regulation through the PI3K/Akt pathway .

What are the optimal conditions for using Phospho-ZFP36L1 (S92) antibody in Western blotting?

For optimal results when using Phospho-ZFP36L1 (S92) antibody in Western blotting:

For verification of specificity, peptide competition assays can be performed using the phosphopeptide (FRDRSFpSEGGERL) to compete away the specific signal . The observed molecular weight may vary between 36-47 kDa due to multiple phosphorylation states of the protein .

How can researchers validate the specificity of Phospho-ZFP36L1 (S92) antibody?

Multiple validation approaches should be employed to ensure antibody specificity:

• Peptide competition assay:

  • Pre-incubate antibody with the phosphopeptide containing the S92 residue (FRDRSF[p]SEGGERL)

  • The specific signal should be competitively blocked while non-phospho-specific antibodies remain unaffected

• Phosphatase treatment control:

  • Treat half of your sample with lambda phosphatase before Western blotting

  • Signal should diminish in treated samples but remain in untreated controls

• Genetic validation:

  • Compare wild-type ZFP36L1 to S92A mutant expression

  • The S92A mutant should not be recognized by the phospho-specific antibody

• Signaling pathway modulation:

  • Stimulate cells with insulin to activate PKB and increase phosphorylation

  • Pre-treat with PI3K inhibitors like wortmannin to decrease phosphorylation

  • Monitor changes in signal intensity corresponding to pathway activity

• Dot blot analysis:

  • Test against multiple peptides: ZFP36L1 (phospho S92), ZFP36L1 non-phospho, and phosphopeptides from other sites (e.g., S125)

  • Antibody should only recognize the phospho S92 peptide

These validation steps are crucial for ensuring that experimental results reflect true biological phenomena rather than non-specific antibody interactions.

What are the recommended procedures for immunoprecipitation using Phospho-ZFP36L1 (S92) antibody?

For successful immunoprecipitation of phosphorylated ZFP36L1:

• Cell stimulation and lysis:

  • Stimulate cells with insulin (100 nM for 15 min) to activate PKB signaling

  • Lyse cells in buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, with added protease and phosphatase inhibitors

  • Clear lysate by centrifugation (14,000 g, 10 min, 4°C)

• Pre-clearing and antibody binding:

  • Pre-clear lysate with Protein A/G beads (1 hour, 4°C with rotation)

  • Incubate pre-cleared lysate with Phospho-ZFP36L1 (S92) antibody (2-5 μg per 1 mg of protein) overnight at 4°C

  • Add fresh Protein A/G beads and incubate for 2-4 hours at 4°C

• Washing and elution:

  • Wash beads 4-5 times with lysis buffer

  • Elute proteins with SDS sample buffer by heating at 95°C for 5 minutes

  • Analyze by Western blotting using either phospho-specific or total ZFP36L1 antibodies

• Controls to include:

  • IgG control immunoprecipitation

  • Input sample (5% of starting material)

  • Phosphatase-treated sample to confirm specificity

  • S92A mutant-expressing cells as negative control

This procedure is particularly useful for studying protein-protein interactions, such as the binding of 14-3-3 proteins to phosphorylated ZFP36L1, which occurs following S92 phosphorylation .

How does Phospho-ZFP36L1 (S92) status affect mRNA decay kinetics in vitro and in vivo?

The phosphorylation state of ZFP36L1 at S92 critically impacts mRNA decay kinetics through several mechanisms:

In vitro decay kinetics:

• Unphosphorylated recombinant ZFP36L1 (rBRF1-wt) promotes rapid degradation of ARE-containing mRNAs in cell-free decay assays

• Phosphorylated rBRF1-wt (p-rBRF1-wt) shows significantly reduced decay-promoting activity

• The S92A mutant of ZFP36L1 maintains decay-promoting activity even after PKB treatment, confirming the specific role of S92 phosphorylation in this regulation

In vivo mRNA stability regulation:

• Insulin stimulation leads to PKB activation and ZFP36L1 phosphorylation at S92

• This phosphorylation correlates with stabilization of ARE-containing mRNAs

• Constitutively active PKB promotes ZFP36L1 phosphorylation and target mRNA stabilization, while kinase-dead PKB variants do not

• The phosphorylation creates a binding site for 14-3-3 proteins, sequestering ZFP36L1 from the decay machinery

Researchers can monitor these effects by measuring the half-life of known ZFP36L1 target mRNAs (e.g., HIF1A, CCND1, E2F1) in cells expressing wild-type versus S92A mutant ZFP36L1, or under conditions of PKB/Akt activation versus inhibition .

What is the role of phosphorylated ZFP36L1 in cancer progression and its potential as a therapeutic target?

Phosphorylated ZFP36L1 plays complex roles in cancer biology:

Tumor suppressive functions:

• ZFP36L1 functions as a tumor suppressor by destabilizing mRNAs of oncogenic transcripts

• Key targets include HIF1A (hypoxia response), CCND1 (cell cycle regulation), and E2F1 (proliferation)

• Forced expression of ZFP36L1 in cancer cells reduces proliferation both in vitro and in vivo

• ZFP36L1 is frequently mutated, epigenetically silenced, and downregulated in various cancers

Oncogenic functions via phosphorylation:

• Phosphorylation at S92 inactivates ZFP36L1's mRNA destabilizing function

• This inactivation can promote expression of growth-promoting and anti-apoptotic genes

• In gastric cancer, super-enhancer-driven ZFP36L1 enhances IFN-γ-induced PD-L1 expression, potentially promoting immune evasion

Therapeutic implications:

• Restoring ZFP36L1 expression or activity could suppress tumor growth

• Preventing S92 phosphorylation might enhance ZFP36L1's tumor-suppressive function

• Targeting the upstream PKB/Akt pathway may indirectly activate ZFP36L1

• In immunotherapy contexts, modulating ZFP36L1 could affect PD-L1 expression and immune checkpoint blockade efficacy

These findings suggest that ZFP36L1 phosphorylation status could serve as both a prognostic biomarker and a potential therapeutic target in cancer.

How does ZFP36L1 phosphorylation at S92 interact with other post-translational modifications and protein partners?

ZFP36L1 phosphorylation at S92 participates in a complex network of post-translational modifications and protein interactions:

Interaction with 14-3-3 scaffold proteins:

• S92 phosphorylation creates a docking site for 14-3-3 proteins

• This interaction sequesters ZFP36L1 from the cellular decay machinery

• 14-3-3 binding may alter ZFP36L1 subcellular localization and function

Cross-talk with other phosphorylation sites:

• ZFP36L1 contains multiple phosphorylation sites, including S54, S92, and S203

• When S92 is mutated to alanine, PKB can phosphorylate the alternative S90 site, though with reduced efficiency

• MAPKAPK2 can phosphorylate ZFP36L1 at S54, S92, and S203, inhibiting mRNA binding while stabilizing the protein

Complex formation with the exosome:

• Unphosphorylated ZFP36L1 recruits the exosome to ARE-containing mRNAs to promote their degradation

• Phosphorylation disrupts this interaction, stabilizing target transcripts

Subcellular localization changes:

• In asthma and under glucocorticoid exposure, ZFP36L1 shows increased nuclear localization

• This compartmentalization affects its ability to regulate cytoplasmic mRNA decay

Protein stability regulation:

• Phosphorylation affects ZFP36L1 protein levels, likely through proteasomal degradation mechanisms

• mTOR inhibition affects ZFP36L1 phosphorylation and protein levels during oncogene-induced senescence

Understanding these interactions is crucial for developing strategies to modulate ZFP36L1 function in therapeutic contexts.

What are the differences in detection and function of phosphorylated ZFP36L1 between normal and disease states?

The detection and function of phosphorylated ZFP36L1 vary significantly between normal and pathological conditions:

Normal physiological state:

• Baseline phosphorylation is low in serum-starved or unstimulated cells

• Rapidly increases following growth factor or insulin stimulation via PKB/Akt activation

• Functions in regulating normal cellular responses to external stimuli

• Maintains proper mRNA decay kinetics of inflammatory and growth-related transcripts

Cancer:

• ZFP36L1 is frequently mutated, epigenetically silenced, or downregulated

• Phosphorylation status may be altered due to constitutive activation of the PI3K/Akt pathway

• Super-enhancer-driven ZFP36L1 in gastric cancer promotes PD-L1 expression

• Detection of phosphorylated ZFP36L1 may serve as a biomarker for aberrant PKB/Akt signaling

Asthma and inflammatory conditions:

• ZFP36L1 and ZFP36L2 mRNAs show decreased binding to polyribosomes in bronchial epithelial cells from severe asthma patients

• Nuclear localization of ZFP36L1/L2 is increased in airways of mice with asthma-like characteristics

• Expression levels are downregulated in chronic House Dust Mite exposure models of asthma

• Glucocorticoids (common asthma treatment) induce ZFP36L1 and ZFP36L2 expression

Immune regulation:

• Acts as a sensor of TCR affinity in CD8 T cells, establishing dominance of high-affinity T cell clones

• Suppresses multiple negative regulators of cytokine signaling and mediates selection based on IL-2 competition

These contextual differences highlight the importance of understanding ZFP36L1 phosphorylation in specific disease settings.

How do researchers address cross-reactivity concerns when using Phospho-ZFP36L1 (S92) antibodies?

Cross-reactivity presents a significant challenge when working with phospho-specific antibodies. Researchers can address these concerns through:

Comprehensive validation strategies:

• Peptide array testing:

  • Screen antibody against multiple phosphopeptides from ZFP36L1 and related proteins

  • Document cross-reactivity profiles with closely related sequences

• Peptide competition assays:

  • Test specificity using dot blot analysis with:

    • ZFP36L1 (phospho S92) peptide

    • ZFP36L1 non-phospho peptide

    • ZFP36L1 (phospho S125) peptide

    • Other related phosphopeptides

• Genetic validation models:

  • Compare results from wild-type, S92A mutant, and ZFP36L1 knockout systems

  • Absence of signal in the S92A mutant confirms specificity

• Paralogue specificity testing:

  • Test against related family members (ZFP36/TTP and ZFP36L2)

  • The S92 region differs between ZFP36L1 and TTP (not present in TTP)

  • Potential cross-reactivity with ZFP36L2 should be evaluated as it shares sequence homology

• Signaling pathway modulation:

  • Activate or inhibit the PKB/Akt pathway and confirm expected changes in signal intensity

  • Treatment with PI3K inhibitors like wortmannin should reduce signal

By combining these approaches, researchers can establish the specificity profile of their antibody and correctly interpret experimental results.

What are the latest techniques for studying the dynamic regulation of ZFP36L1 phosphorylation in single cells?

Recent technological advances have enabled more sophisticated analysis of ZFP36L1 phosphorylation dynamics:

Single-cell phosphoproteomics:

• Mass spectrometry-based approaches with increased sensitivity allow detection of phosphorylated ZFP36L1 from minimal sample input

• Single-cell mass cytometry (CyTOF) can be adapted for phosphorylated ZFP36L1 detection alongside other signaling markers

• Requires careful antibody validation and optimization of metal-conjugated antibodies

Live-cell imaging approaches:

• FRET-based biosensors designed to report on ZFP36L1 phosphorylation state

• Construction of sensors containing:

  • ZFP36L1 fragment containing the S92 region

  • 14-3-3 binding domain

  • Appropriate fluorescent protein pairs

• Changes in FRET signal indicate dynamic phosphorylation/dephosphorylation events

Phospho-specific intracellular flow cytometry:

• Enables quantitative assessment of phosphorylated ZFP36L1 in heterogeneous cell populations

• Can be combined with cell surface markers to identify specific cell subsets

• Particularly useful for studying ZFP36L1 phosphorylation in T cell activation where it functions as a TCR affinity sensor

Single-cell RNA sequencing integration:

• Combine phospho-flow or CyTOF data with scRNA-seq to correlate ZFP36L1 phosphorylation status with transcriptional effects

• Allows identification of cell state-specific ZFP36L1 activity

• Can reveal heterogeneity in mRNA target regulation within seemingly homogeneous populations

Subcellular fractionation with Frac-seq:

• Enables study of ZFP36L1's impact on mRNA distribution between cytoplasmic, monosomal, and polyribosomal fractions

• Reveals post-transcriptional regulatory effects that might be missed by total RNA analysis

These emerging technologies provide unprecedented insights into how ZFP36L1 phosphorylation dynamically regulates cellular processes in complex tissues and heterogeneous cell populations.

What are common pitfalls when working with Phospho-ZFP36L1 (S92) antibodies and how can they be avoided?

Researchers frequently encounter several challenges when working with phospho-specific antibodies:

Challenge: Loss of phosphorylation signal

• Cause: Endogenous phosphatase activity during sample preparation

• Solution: Always include fresh phosphatase inhibitors in lysis buffers

• Implementation: Use cocktails containing sodium fluoride, sodium orthovanadate, and β-glycerophosphate

Challenge: High background in Western blots

• Cause: Cross-reactivity with similar phospho-epitopes

• Solution: Optimize blocking conditions and antibody dilution

• Implementation: Test both 5% BSA and 5% non-fat dry milk as blocking agents; typically, BSA is preferred for phospho-antibodies

Challenge: Inability to detect signal in fixed tissues

• Cause: Phospho-epitope masking during fixation

• Solution: Optimize antigen retrieval methods

• Implementation: Test different retrieval buffers (citrate, EDTA, Tris) and heating methods

Challenge: Inconsistent results between experiments

• Cause: Variation in phosphorylation state due to cell culture conditions

• Solution: Standardize cell stimulation protocols

• Implementation: Use consistent serum starvation periods (e.g., overnight) followed by precise stimulation timing

Challenge: Discrepancies between antibody lots

• Cause: Variability in antibody production

• Solution: Validate each new lot against previous standards

• Implementation: Maintain positive control lysates from cells with known ZFP36L1 phosphorylation status

Challenge: Limited signal in immunofluorescence applications

• Cause: Low abundance of phosphorylated protein

• Solution: Signal amplification techniques

• Implementation: Consider tyramide signal amplification or polymer detection systems

Proper sample handling is particularly critical - phosphorylation states can change rapidly after cell lysis, so samples should be processed quickly with immediate addition of SDS sample buffer or flash freezing in liquid nitrogen.

How can researchers accurately quantify changes in ZFP36L1 phosphorylation across experimental conditions?

Accurate quantification of ZFP36L1 phosphorylation requires robust methodological approaches:

Western blot quantification best practices:

• Always run total ZFP36L1 and phospho-ZFP36L1 (S92) blots in parallel

• Calculate phospho-to-total ratio to normalize for changes in total protein expression

• Include loading controls (e.g., GAPDH, β-actin) for additional normalization

• Use digital imaging systems with linear detection range rather than film

• Perform replicate experiments (minimum n=3) for statistical analysis

Alternative quantitative approaches:

• ELISA-based methods:

  • Commercial or custom sandwich ELISAs using capture antibodies against total ZFP36L1 and detection with phospho-specific antibodies

  • Provides more quantitative results than Western blotting

• Mass spectrometry quantification:

  • Targeted MS approaches using isotope-labeled reference peptides

  • Allows absolute quantification of phosphorylated versus non-phosphorylated peptides

  • Can simultaneously detect multiple phosphorylation sites

• Bead-based flow cytometry:

  • Multiplex detection of total and phosphorylated ZFP36L1 alongside other signaling proteins

  • Enables high-throughput analysis across multiple samples and conditions

Experimental design considerations:

• Include appropriate positive controls (insulin-stimulated samples)

• Include negative controls (wortmannin pre-treated samples)

• Use S92A mutant-expressing cells as specificity controls

• Consider time-course experiments to capture dynamic changes

• Include dose-response studies when examining pathway modulators

Data normalization strategies:

• For kinetic studies, normalize to maximum stimulation

• For cross-condition comparisons, use internal reference standards

• When comparing across cell types, consider normalization to pathway activity markers

These rigorous approaches ensure that observed changes in ZFP36L1 phosphorylation accurately reflect biological phenomena rather than technical artifacts.

What are the considerations for developing and validating novel assays to study ZFP36L1 phosphorylation in different biological systems?

Developing robust assays for studying ZFP36L1 phosphorylation across diverse biological contexts requires careful consideration:

Assay development framework:

• Target identification and validation:

  • Confirm the presence of ZFP36L1 in your biological system

  • Verify that the S92 site is conserved if working with non-human models

  • Evaluate baseline expression levels to determine assay sensitivity requirements

• Antibody qualification:

  • Test commercial phospho-specific antibodies across applications

  • Consider developing custom antibodies if needed

  • Validate specificity using peptide competition, S92A mutants, and phosphatase treatment

• Signal detection optimization:

  • Determine minimal detectable phosphorylation levels

  • Establish signal-to-noise ratios across detection methods

  • Define linear dynamic range of the assay

• Biological validation:

  • Confirm expected phosphorylation changes with pathway modulation

  • Demonstrate biological consequences of phosphorylation

  • Correlate assay results with functional outcomes

System-specific considerations:

Emerging technologies to consider:

• Proximity ligation assays to detect protein-protein interactions dependent on phosphorylation status

• CRISPR-based reporters of ZFP36L1 activity linked to phosphorylation

• Nanobody-based detection systems for improved penetration and specificity

• Bio-orthogonal labeling strategies for newly synthesized or modified ZFP36L1

Regardless of the biological system, thorough validation with appropriate controls and rigorous quantification are essential for developing reliable assays to study ZFP36L1 phosphorylation dynamics.

What emerging roles of ZFP36L1 phosphorylation are being investigated beyond established functions in mRNA decay?

Research is uncovering novel functions of phosphorylated ZFP36L1 beyond its canonical role in mRNA decay:

Transcriptional regulation:

• Increased nuclear localization of ZFP36L1 in disease states suggests potential transcriptional roles

• Investigation of potential DNA-binding activity or interaction with transcriptional machinery

• Examination of whether phosphorylation affects chromatin association patterns

Immune checkpoint regulation:

• Super-enhancer-driven ZFP36L1 enhances IFN-γ-induced PD-L1 expression in gastric cancer

• Possible modulation of other immune checkpoint molecules through similar mechanisms

• Potential role in tumor immune evasion and response to immunotherapy

T cell selection and memory formation:

• ZFP36L1 acts as a sensor of TCR affinity to promote clonal expansion of high-affinity CD8 T cells

• Phosphorylation may regulate this function and impact immunological memory

• Targeting ZFP36L1 could potentially enhance vaccine efficacy or CAR-T cell responses

Cellular stress responses:

• Possible involvement in stress granule formation and regulation

• Interaction with the integrated stress response pathway

• Role in determining cell fate decisions under stress conditions

Non-coding RNA regulation:

• Potential binding and regulation of miRNAs, lncRNAs, and other non-coding RNAs

• Phosphorylation may alter these interactions and downstream effects

• Investigation of ZFP36L1 in competing endogenous RNA networks

Translation regulation:

• Emerging evidence suggests ZFP36L1/L2 modulate distinct mRNA targets in a subcellular-dependent manner

• Potential role in regulating monosome binding and polyribosome association of specific mRNAs

• Phosphorylation may affect these translational regulatory functions

These emerging areas represent exciting frontiers in understanding the multifaceted roles of ZFP36L1 phosphorylation in cellular function and disease.

How might advances in structural biology enhance our understanding of ZFP36L1 phosphorylation and drug development?

Structural biology approaches offer powerful insights into ZFP36L1 function and therapeutic targeting:

Current structural knowledge gaps:

• Full-length crystal structures of ZFP36L1 in both phosphorylated and unphosphorylated states are lacking

• Structural basis for how S92 phosphorylation affects RNA binding remains unclear

• Molecular details of the interaction between phosphorylated ZFP36L1 and 14-3-3 proteins need elucidation

Emerging methodologies with promising applications:

• Cryo-electron microscopy (Cryo-EM):

  • Could resolve structures of ZFP36L1 complexes with 14-3-3 proteins

  • May visualize conformational changes induced by phosphorylation

  • Potential to capture dynamic states during mRNA decay

• AlphaFold and other AI prediction tools:

  • Generate models of full-length ZFP36L1 in different phosphorylation states

  • Predict structural changes upon S92 phosphorylation

  • Model interactions with binding partners and mRNA targets

• Solution NMR spectroscopy:

  • Ideal for studying the dynamics of zinc finger domains

  • Can probe subtle structural changes upon phosphorylation

  • Potentially resolve disordered regions that may become ordered upon binding

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS):

  • Map conformational changes induced by phosphorylation

  • Identify regions with altered solvent accessibility

  • Provide insights into allosteric effects of S92 phosphorylation

Implications for drug development:

• Structure-based design of molecules that:

  • Prevent S92 phosphorylation without affecting RNA binding

  • Disrupt the interaction between phosphorylated ZFP36L1 and 14-3-3

  • Mimic the effects of ZFP36L1 on target mRNAs

• Potential therapeutic strategies:

  • Small molecules targeting the S92 region to prevent phosphorylation

  • Peptide mimetics of the 14-3-3 binding site to compete for binding

  • Engineered ZFP36L1 variants with altered phosphorylation properties

  • RNA aptamers that selectively bind and modulate ZFP36L1 function

Structural insights could reveal allosteric sites that might be more druggable than the phosphorylation site itself, opening new avenues for therapeutic intervention in cancer, inflammation, and other diseases where ZFP36L1 dysfunction plays a role.

What technological developments are needed to better understand the dynamic interplay between ZFP36L1 phosphorylation and cellular pathways?

Several technological advances would significantly enhance our understanding of ZFP36L1 phosphorylation dynamics:

Real-time phosphorylation sensors:

• Development of genetically encoded biosensors specifically for ZFP36L1 S92 phosphorylation

• FRET-based or fluorescent protein-based reporters that change signal upon phosphorylation

• Integration with optogenetic tools to allow spatial and temporal control of phosphorylation

Single-molecule tracking technologies:

• Methods to visualize individual ZFP36L1 molecules and their interaction with mRNAs

• Tracking phosphorylation state and protein-protein interactions at the single-molecule level

• Correlating molecular behavior with functional outcomes in living cells

Multi-omics integration platforms:

• Computational frameworks that integrate phosphoproteomics, transcriptomics, and ribosome profiling

• Systems biology approaches to model the effects of ZFP36L1 phosphorylation on cellular networks

• Machine learning algorithms to predict ZFP36L1 targets and regulatory outcomes

Advanced tissue imaging technologies:

• Multiplexed imaging to simultaneously visualize ZFP36L1 phosphorylation and downstream effects

• Spatial transcriptomics to map ZFP36L1 activity within complex tissues

• In situ sequencing to identify ZFP36L1-regulated mRNAs in their native context

Engineered cellular systems:

• CRISPR-based approaches for endogenous tagging of ZFP36L1

• Rapid induction systems to trigger or inhibit phosphorylation

• Synthetic biology platforms to reconstitute ZFP36L1 regulatory circuits

Needed methodological improvements:

• Higher sensitivity phospho-proteomic methods to detect low-abundance modifications

• Improved antibody technologies with better specificity and sensitivity

• Non-invasive approaches to monitor phosphorylation in living tissues